10-Q: American Fusion Reports Q2 2026 Results, Faces Going Concern Doubt

American Fusion, Inc. filed its Q2 2026 Form 10-Q, detailing a significant accumulated deficit and recurring operational losses, raising substantial doubt about its ability to continue as a going concern.

Summary

• American Fusion, Inc. (AMFN) filed its quarterly report for the period ended June 30, 2026.
• The company has an accumulated deficit of approximately $10.9 million and has incurred recurring losses from operations, raising substantial doubt about its ability to continue as a going concern.
• Revenue for the three and six months ended June 30, 2026, was $58,000, with a cost of revenue of $50,000, resulting in a gross profit of $8,000.
• Operating expenses for the three months ended June 30, 2026, were $1,253,180, leading to a loss from operations of $1,245,180.
• For the six months ended June 30, 2026, operating expenses were $1,885,763, resulting in a loss from operations of $1,877,763.
• Net loss for the three months ended June 30, 2026, was $1,275,208, and for the six months ended June 30, 2026, it was $1,944,958.
• The company received a Certificate of Registration from the Texas Department of State Health Services for industrial radiation machines for research and development activities, effective through February 28, 2034.
• Cash and cash equivalents increased by $76,816 during the six months ended June 30, 2026, to $79,341, with a working capital deficit of $1,708,451.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant accumulated deficits, recurring losses, and substantial doubt about the company's ability to continue as a going concern, despite some operational milestones.

Positives

• Generated $58,000 in revenue for the three and six months ended June 30, 2026, compared to no revenue in the prior year periods.
• Received a significant operational milestone: Certificate of Registration No. R54726 from the Texas Department of State Health Services for research and development activities related to its Texatron Fusion Engine, effective through February 28, 2034.
• Cash and cash equivalents increased by $76,816 during the six months ended June 30, 2026, reaching $79,341.
• Secured $1,168,000 in cash from financing activities during the six months ended June 30, 2026, primarily from prepaid warrant funding ($943,000) and equity unit sales ($225,000).

Negatives

• The company has an accumulated deficit of approximately $10.9 million as of June 30, 2026.
• Incurred recurring losses from operations, raising substantial doubt about the company's ability to continue as a going concern.
• Net loss for the three months ended June 30, 2026, was $1,275,208, and $1,944,958 for the six months ended June 30, 2026.
• Operating expenses significantly outpaced revenue, with $1,253,180 for the three months and $1,885,763 for the six months ended June 30, 2026.
• The company has a working capital deficit of $1,708,451 as of June 30, 2026.
• Convertible notes payable-related party are in default as of June 30, 2026.
• A judgment of $697,341 for litigation liability exists as of June 30, 2026, with the company actively pursuing legal remedies to vacate it.

Risks

• Substantial doubt exists about the Company's ability to continue as a going concern due to its accumulated deficit and recurring losses.
• The Company requires substantial additional capital to fund its operations and commercialization of its fusion energy technology.
• The Company's net operating loss carryforwards may be limited under IRC Section 382 due to a change in control on February 27, 2026.
• The Company is in an early stage of development with limited operating history.
• The Texas Department of State Health Services registration authorizes research and development activities only and does not constitute certification of the Company's technology or commercial performance.
• The Company is subject to significant financial, operational, regulatory, and technological risks.

Future Outlook

The company expects to require substantial additional capital to fund its research and development activities, prototype testing, intellectual property filings, and preparation for commercial deployment. Management is actively pursuing financing opportunities, including a previously announced $50 million capital raise. The Texas Department of State Health Services registration is for research and development activities only and does not certify commercial performance.

Management Comments

• Management believes that after the completion of the Kepler business merger the planned capital-raising activities will provide the resources necessary to fund ongoing operations; however, no assurance can be given that these plans will be successful.
• Management believes receipt of the registration represents a significant operational milestone supporting the continued engineering, prototype testing, technical validation and research activities associated with its Texatron Fusion Engine development program.
• Management is actively pursuing financing opportunities, including the previously announced $50 million capital raise.

Industry Context

StockSavvy.ai notes that American Fusion operates in the nascent but high-potential fusion energy sector. The company's focus on the Texatron compact pulsed toroidal fusion reactor and a Power-as-a-Service model positions it within a segment aiming for clean, scalable baseload electricity. However, the significant accumulated deficit and ongoing losses highlight the substantial capital requirements and long development timelines typical of this industry.

Comparison to Industry Standards

• The company's revenue of $58,000 for the six months ended June 30, 2026, is minimal compared to established energy providers, reflecting its early-stage development.
• The significant operating expenses ($1,885,763 for six months) are consistent with companies investing heavily in research and development for novel technologies like fusion energy.
• The accumulated deficit of $10.9 million is substantial for a company at this stage, indicating a high burn rate typical of deep-tech ventures requiring significant upfront investment before commercialization.
• The company's reliance on financing activities ($1,168,000 in the period) is common for companies in capital-intensive, long-term development cycles, aiming to bridge the gap until revenue generation is sufficient.

Legal Proceedings

• The Company is actively pursuing legal remedies to vacate a judgment entered by the Court of Alaska on December 12, 2024, for $618,994, plus accrued interest, on the grounds that the underlying asset purchase agreement was never consummated and no assets were delivered.
• In April 2026, the Company obtained an amended default judgment rescinding certain legacy asset purchase agreements and declaring void ab initio the prior issuance of 1,683,000,000 shares of common stock.

Related Party Transactions

• Consulting agreement with Brent Nelson (CEO of Kepler) for $15,000 per month, with $45,000 and $60,000 paid in the three and six months ended June 30, 2026, respectively.
• An entity controlled by Brent Nelson holds the Special 2020 Series A Preferred Share, which carries 60% voting power.
• An immediate family member of Mr. Nelson was paid $15,000 for marketing-related services in the three and six months ended June 30, 2026.
• Promissory notes issued to CMB Communications, LLC (controlled by CEO) for accrued compensation, with principal outstanding of $213,692 at June 30, 2026.
• Consulting agreement with RH2 Equity Partners, LP (controlled by CEO) for a $20,000 cash fee, retention of outstanding notes, and issuance of 1,000,000 shares of common stock vesting over 36 months.
• Issuance of 450,000 shares to CMB Communications LLC and 550,000 shares to Pinnacle Consulting Services, Inc. for conversion of indebtedness.
• Pinnacle Consulting Services, Inc. converted $25,000 of principal into 125,000,000 shares of common stock.
• Pinnacle Consulting Services, Inc. returned 20,000,000 shares to the Company at no cost.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern issues and substantial accumulated deficit.
• The company's ability to secure future funding is critical for its continued operations and potential success, impacting all stakeholders.
• The ongoing litigation liability could potentially impact the company's financial resources if not successfully resolved.
• The issuance of new shares for financing and compensation could lead to further dilution for existing shareholders.

Next Steps

• Continue research and development, prototype testing, and intellectual property expansion.
• Prepare for commercial deployment of the Texatron Fusion Engine.
• Pursue planned capital-raising activities, including the $50 million capital raise.
• Commence research testing activities at the authorized testing location in Lubbock, Texas, following receipt of the radiation machine registration.

Key Dates

Recommendation

The company shows progress in R&D with a key regulatory approval, but the severe going concern issues, significant accumulated deficit, and recurring losses necessitate a cautious approach. While there's potential in fusion technology, the immediate financial health and need for substantial capital raise make it a speculative investment. A 'hold' recommendation reflects the balance between potential upside and significant downside risk.

Keywords

fusion energy, Texatron, research and development, quarterly report, financial statements, going concern, capital raise, Texas